Journal News

JLR: Using microRNAs to target cancer cells

Dawn Hayward
March 1, 2016

Lipids form the membranes of our cells and serve as rainy day fuel. However, cancer cells have a habit of dysregulating every possible pathway they can, including lipid metabolism, generating an overabundance of lipids. Fortunately, the body already produces molecules that have the potential to stop this dysregulation in its tracks: microRNAs.

Summary of the metabolic pathways altered in cancer that are described in this review

In a recent review in the Journal of Lipid Research, Marta Gómez de Cedrón and Ana Ramírez de Molina of the Madrid Institute of Advanced Studies delve into exactly which microRNAs can be used to target cancer cells.

Lipids, molecules known for their insolubility in water, are synthesized to provide membrane integrity and are signaling molecules used by downstream effectors in the cell. As an energy source, lipids are broken down via beta-oxidation, and the intermediates can be used in other metabolic pathways.

MicroRNAs, meanwhile, are small single-stranded RNA molecules that can stop the synthesis of proteins. They bind to mRNA transcripts in the cell and cause their degradation, preventing production of proteins that cancer cells so desperately need.

The authors of the JLR review discuss several lipid-metabolism enzymes that cancer cells rely on whose targeting could prevent the synthesis and dissemination of lipids altogether. For example, an enzyme called fatty acid synthase, which is involved in the making of lipids, is upregulated and overused in cancer cells. Activation of a microRNA targeting this gene may shut down production of this enzyme and turn off this essential pathway. Mono-acyl glycerol lipase, which is involved in storing these lipids, may also be targeted.

Why is all of this important? If researchers can use normal cells’ machinery to target cancer cells specifically, the cancer may be slowed or completely halted. In fact, scientists have used antisense oligonucleotides that bind to microRNAs and repress their action as well as primary microRNAs, which mimic RNA of choice and activate their function. These methods have been used as cancer therapy in clinical trials.

MicroRNAs stand out from conventional gene-therapy-based approaches and have a niche in lipid metabolism. They can be designed specifically to target a gene and serve as modulators rather than on/off switches. Increased lipid formation and breakdown in cancer cells creates vulnerability that might be taken advantage of by microRNAs. In addition, cancer as a whole involves a combination of many factors, and microRNAs could lead the attack as professional pathway regulators to reset the normal metabolic landscape.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Dawn Hayward

Dawn Hayward earned a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Study finds why immunotherapies don’t work on hardest-to-treat breast cancers
News

Study finds why immunotherapies don’t work on hardest-to-treat breast cancers

Feb. 4, 2023

“The tumor completely changes after chemotherapy treatment into this thing that is essentially built to block the immune system,” study author James Jackson of Tulane University said.

Structural insights reveal how SPOP protein contributes to cancer
News

Structural insights reveal how SPOP protein contributes to cancer

Feb. 2, 2023

St. Jude team publishes the first 3D structure of the entire assembly.

Common psychotropic meds disrupt cholesterol synthesis in brain
Journal News

Common psychotropic meds disrupt cholesterol synthesis in brain

Jan. 31, 2023

Mouse study explains why adults sometimes get misdiagnosed with rare syndrome that affects babies.

Could getting rid of old cells turn back the clock on aging?
Feature

Could getting rid of old cells turn back the clock on aging?

Jan. 29, 2023

Researchers are investigating medicines that selectively kill decrepit cells to promote healthy aging — but more work is needed before declaring them a fountain of youth.

Neurodegenerative disease linked to microtubules
Journal News

Neurodegenerative disease linked to microtubules

Jan. 26, 2023

A team at McGill University reports a new role for sacsin, the protein mutated in a rare hereditary ataxia.